StreetInsider.com  Sep 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Cubist+Pharma+%28CBST%29%2C+Optimer+%28OPTR%29+Report+Expiration+of+HSR+Act+in+Proposed+Merger/8686287.html for the full story.
StreetInsider.com  Aug 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Optimer+Pharmaceuticals+%28OPTR%29+Tops+Q2+EPS+by+7c/8559208.html for the full story.
Forbes  Jul 31  Comment 
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
Benzinga  Jul 31  Comment 
In a report published Wednesday, Jefferies analyst Eun K. Yang downgraded Optimer Pharmaceuticals (NASDAQ: OPTR) from Buy to Hold, and lowered the price target from $17.00 to $13.25. In the report, Jefferies noted, “Given anticipated OPTR...
Benzinga  Jul 31  Comment 
In a report published Wednesday, Canaccord Genuity analyst Ritu Baral downgraded Optimer Pharmaceuticals (NASDAQ: OPTR) from Buy to Hold, and lowered the price target from $22.00 to $13.00. In the report, Canaccord Genuity noted, “Lowering...
Benzinga  Jul 31  Comment 
Riverbed Technology (NASDAQ: RVBD) dipped 17.46% to $14.47 in the pre-market session after the company reported downbeat second-quarter revenue. Optimer Pharmaceuticals (NASDAQ: OPTR) shares fell 6.47% to $12.43 in the pre-market trading after...
New York Times  Jul 31  Comment 
After Cubist Pharmaceuticals announced it would buy Trius Therapeutics and Optimer Pharmaceuticals to strengthen its antibiotics portfolio, its shares rose in after-hours trading.     
Benzinga  Jul 30  Comment 
After the close Tuesday, Cubist Pharmaceuticals (NASDAQ: CBST) announced its intention to acquire two separate companies, Trius Therapeutics (NASDAQ: TSRX) and Optimer Pharmaceuticals (NASDAQ: OPTR) for a combined total potential value of $1.619...
FierceBiotech  Jul 30  Comment 
Cubist Pharmaceuticals surprised some analysts with the announcements of two major acquisitions Tuesday afternoon, agreeing to buy both Trius Therapeutics and Optimer Pharmaceuticals to build its antibiotics business. The combined deal values $1.6...
Benzinga  Jul 30  Comment 
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that they have signed a merger agreement under which Cubist will acquire all of the outstanding shares of Optimer common stock for $10.75...


Optimer Pharmaceuticals Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. The company is currently focused on the development of products that treat gastrointestinal (GI) infections and related diseases where current therapies have limitations, including diminished efficacy, serious adverse side effects, drug-to-drug interactions, difficult patient compliance and bacterial resistance. Optimer has two late-stage anti-infective product candidates, Difimicin and Prulifloxacin. Difimicin (OPT-80) is an antibiotic currently in a phase III registration trial for the treatment of Clostridium difficile-associated diarrhea (CDAD), the most common nosocomial, or hospital-acquired, diarrhea. Prulifloxacin is an antibiotic currently in two phase III trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Optimer is also developing additional product candidates using its proprietary technology, including Optimer One-Pot Synthesis (OPopS) drug discovery platform. The following table summarizes the major clinical/preclinical drug candidates:

Product Candidate

Target Indications

Development Status

Commercial Rights


Difimicin (OPT-80)

CDAD treatment

Phase III

Optimer worldwide

CDAD prevention

Proof-of-concept Trial

Prevention of VRE bloodstream infections

Proof-of-concept Trial

MRS prophylaxis

Nasal carriage




Prulifloxacin (OPT-99)

Infectious diarrhea

Phase III

Optimer U.S.


Respiratory tract infections


Cempra worldwide

Other Therapeutics


Breast cancer

Planning Phase II

Optimer worldwide




Optimer worldwide

In February, 2007, Optimer went public by issuing 7 million shares of common stock at a price of $7.00 per share, resulting in aggregate proceeds of approximately $43.6 million, net of underwriting discounts and commissions and offering expenses. In addition, in February 2007, the underwriters exercised in full the over-allotment option to purchase an additional 1.1 million shares of the company's common stock from a selling stockholder.

Optimer was incorporated in Delaware in November, 1998 and is headquartered in San Diego, California. Optimer has a wholly owned subsidiary, Optimer Biotechnology, Inc., in Taiwan.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki